Alaya.bio at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Alaya.bio brings 3 presentations to ESGCT 2026 in Hamburg. Its work centres on making CAR T cells inside the body, using polymer-modified lentiviral particles that home to the intended cells. A second strand sets out a manufacturing route for those particles aimed at faster movement into the clinic.
| Organization | ESGCT 2026 Attendance |
|---|---|
Alaya.bio New York, New York | |
Develops in vivo CAR-T therapies that use targeted polymeric nanoparticles to reprogram T cells inside the patient; R&D in Villejuif, France. | Poster Wed Oct 28 1:30pm–3:30pm An integrated manufacturing platform for lentiviral vectors-based nanoparticle enabling accelerated clinical translation for in situ gene delivery therapies Poster Wed Oct 28 1:30pm–3:30pm In vivo polymeric gene delivery platform for targeted cell reprogramming in hematological malignancies Poster Thu Oct 29 2:00pm–4:00pm Lentivector engineering with polymer surface modification for targeted in vivo CAR-T cell therapy |
Instantly find 20 buyers from Alaya.bio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction